Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271492 · ClinicalTrials.gov registry record · Phase 3
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
A Phase 3 study of Endothelial Dysfunction, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00271492: Completed Phase 3 study of Endothelial Dysfunction, sponsored by Mayo Clinic.
NCT00271492 is a Phase 3 study of Endothelial Dysfunction that has completed, run by Mayo Clinic. The registered enrollment target is 200 participants, above the 88-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (127% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00271492, a Phase 3 study of Endothelial Dysfunction, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Qualifying patients who are scheduled for angiogram with endothelial function testing are approached to participate in this protocol (consent form reviewed with patient). Those who are willing to participate will have additional measurements taken during their angiogram as part of this protocol. Patients who are diagnosed with Endothelial Dysfunction as a result of a clinically indicated angiogram will be eligible to participate in a 6 month medication trial (Atrasentan vs. placebo - randomized, blinded trial). Patients are monitored closely during the 6 month trial via phone calls and blood testing for assessment. At the end of the 6 months they return to Mayo for a repeat angiogram to assess endothelial function for any changes or improvements.
Conditions Studied
Interventions
- DRUG Atrasentan
- DRUG atrasentan
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2001-07 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00271492 record still lists
NCT00271492 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (127% higher).
The record links to 1 condition, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Atrasentan is the first listed.
NCT00271492 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00271492 about?
NCT00271492 is a clinical study titled "Correlation of Endothelial Function and Early Coronary Artery Disease in Humans". Qualifying patients who are scheduled for angiogram with endothelial function testing are approached to participate in this protocol (consent form reviewed with patient). Those who are willing to participate will have additional measurements taken during their angiogram as part of this protocol. Pat...
What is the current status of trial NCT00271492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2001-07. Estimated completion is 2008-01.
What conditions does trial NCT00271492 study?
This clinical trial studies the following conditions: Endothelial Dysfunction.
What interventions are being tested in trial NCT00271492?
The interventions under investigation include: Atrasentan (DRUG), atrasentan (DRUG).
Who is sponsoring clinical trial NCT00271492?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00271492 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00271492's enrollment target sits among peer trials
200 4th of 45 higher than 42 of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Role of Endothelial Function in SCI CVD Risk
RECRUITING
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia